RecruitingNCT02753777
Autoimmune Blistering Diseases Study
Prevalence and Clinical Severity of Autoimmune Blistering Diseases
Sponsor
University of Pennsylvania
Enrollment
150 participants
Start Date
Apr 1, 2016
Study Type
OBSERVATIONAL
Conditions
Summary
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the availability of validated disease severity measures that can be used to define primary outcomes.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Gender/Age: Males or females above 18 years old
- Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid
- Subjects able to give informed consent
Exclusion Criteria5
- Patients who are under age 18 years.
- Patients without pemphigus or pemphigoid diseases
- Penn employees
- Penn students
- Cognitively impaired persons
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERQuestionnaires
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02753777
Related Trials
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
NCT0442291213 locations
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
NCT065815621 location
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT056352661 location